GO:0022857 transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0022857 transmembrane transporter activity describes the molecular function that enables transfer of a substance, usually a specific substrate or group of related substrates, from one side of a membrane to the other.
• Transporters are integral membrane proteins that mediate uptake and efflux of ions, nutrients, drugs, and signaling molecules, and they are central to pharmacokinetics and natural product-drug interactions.
• Secondary active transport couples substrate movement to ion or lipid gradients, and structural studies reveal how ion and lipid orchestration controls conformational cycles.
• Defects in specific transporters cause human disease, including manganese efflux deficiency (SLC30A10) and impaired ER magnesium uptake (TMEM94/ERMA) [2,4].
• Urea transporters illustrate how distinct inhibition modes can be exploited for drug development, and TRIAC transport is mediated by specific human transporters [3,7].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal testing of transporter gene function in disease and drug response [1,2,4].
Description
Transmembrane transporter activity (GO:0022857) is a molecular function that enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. This activity is fundamental to cellular physiology because it controls the movement of ions, nutrients, metabolites, and xenobiotics across biological membranes, thereby shaping signaling, metabolism, and drug disposition [1,8]. Transporters are integral membrane proteins that undergo conformational changes to move substrates, and their dysfunction is linked to diverse human disorders [2,4]. Researchers study transmembrane transporter activity to understand substrate specificity, transport mechanisms, and the impact of genetic variants on transport function [3,8]. The term encompasses substrate-specific transmembrane transporter activity, substrate-specific transporter activity, uptake permease activity, and uptake transmembrane transporter activity, reflecting the broad range of transport processes across membranes. Because transporters are often drug targets or determinants of drug absorption and elimination, they are a major focus in pharmacology and drug development [1,7].
transmembrane transporter activity At A Glance
| GO ID | GO:0022857 |
|---|---|
| GO term | transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | substrate-specific transmembrane transporter activity; substrate-specific transporter activity; uptake permease activity; uptake transmembrane transporter activity |
| Major function | Enables transfer of a substance, usually a specific substance or group of related substances, from one side of a membrane to the other |
| Substrate types | Ions, nutrients, metabolites, drugs, and other small molecules |
| Transport modes | Passive facilitated diffusion and active transport (primary and secondary) |
| Cellular location | Integral membrane proteins in plasma and organelle membranes |
| Representative genes | SLC30A10, TMEM94 (ERMA), SLC14A1, SLC14A2, SLC5A1, SLC2A1, LptC, and others |
What Is GO:0022857?
GO:0022857 transmembrane transporter activity is defined as enabling the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. This molecular function is carried out by integral membrane proteins that facilitate or actively pump substrates across lipid bilayers. The activity is substrate-specific in many cases, meaning that a given transporter recognizes a particular ion, nutrient, or drug, although some transporters handle a group of related substances [1,8]. Transport can be passive (facilitated diffusion) or active (primary or secondary active transport), and the term covers both uptake and efflux processes. The official synonyms include substrate-specific transmembrane transporter activity, substrate-specific transporter activity, uptake permease activity, and uptake transmembrane transporter activity.
Why Is transmembrane transporter activity Important in Cell Biology?
Transmembrane transporter activity is essential for maintaining cellular homeostasis, nutrient uptake, ion gradients, and removal of metabolic waste and xenobiotics [1,8]. Transporters determine the pharmacokinetics of many drugs, and transporter-mediated natural product-drug interactions can alter drug efficacy and toxicity. Genetic defects in transporters cause human diseases, such as manganese efflux deficiency due to SLC30A10 mutations and impaired endoplasmic reticulum magnesium uptake due to TMEM94/ERMA dysfunction [2,4]. Structural and mechanistic studies of transporters, including urea transporters and secondary active transporters, provide a basis for designing inhibitors or modulators with therapeutic potential [3,8]. Therefore, understanding transmembrane transporter activity is critical for physiology, pharmacology, and precision medicine [1,7].
• Controls uptake of nutrients such as glucose and ions across the plasma membrane.
• Mediates efflux of toxic metals, including manganese, via SLC30A10.
• Regulates endoplasmic reticulum magnesium homeostasis through TMEM94/ERMA.
• Determines absorption, distribution, and elimination of drugs and natural products.
• Provides targets for inhibitors, as shown for urea transporters with distinct inhibition modes.
• Couples substrate transport to ion and lipid gradients in secondary active transport.
• Participates in bacterial lipopolysaccharide extraction by the LptB2FGC transporter.
• Enables thyroid hormone analog TRIAC transport by specific human transporters.
• Underlies glucose transport physiology relevant to diabetes and metabolic disease.
• Offers opportunities for CRISPR-based functional validation of transporter genes [1,2,4].
What Happens During transmembrane transporter activity?
Substrate recognition and binding
In simple terms: The transporter first grabs the substance it will move across the membrane.
Transmembrane transporters possess substrate-binding sites that recognize specific ions, nutrients, or drugs, often with high selectivity [1,8]. Structural elements in transmembrane and cytoplasmic domains are required for substrate binding and subsequent transport activity, as shown for the metal transporter SLC30A10. The binding step is the first committed step in the transport cycle and determines substrate specificity.
Conformational cycling and translocation
In simple terms: The transporter changes shape to carry the substance from one side of the membrane to the other.
After substrate binding, transporters undergo conformational changes that move the substrate across the lipid bilayer. Secondary active transporters couple this movement to ion or lipid gradients, and structural studies reveal how ion and lipid orchestration controls the transport cycle. For urea transporters, distinct inhibition modes reveal how conformational states can be targeted by small molecules.
Energy coupling in active transport
In simple terms: Some transporters use energy to pump substances against their concentration gradient.
Primary active transporters, such as P-type ATPases, hydrolyze ATP to drive substrate transport; ERMA (TMEM94) is a P-type ATPase transporter for Mg2+ uptake in the endoplasmic reticulum. Secondary active transporters use pre-existing ion gradients to power substrate movement. This energy coupling allows cells to accumulate substances against their concentration gradients [2,8].
Release and resetting
In simple terms: The transporter releases the substance on the other side and returns to its starting shape.
Following translocation, the substrate is released into the opposite compartment, and the transporter resets to its initial conformation to complete the cycle. This resetting step is essential for continuous transport and can be regulated by ions, lipids, or accessory proteins. In the LptB2FGC transporter, the transmembrane alpha-helix of LptC participates in LPS extraction, illustrating the importance of accessory components in the transport cycle.
Key Genes Involved in GO:0022857 transmembrane transporter activity
The following genes encode representative transporters or transporter subunits that carry out transmembrane transporter activity (GO:0022857) and are supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC30A10 | Manganese efflux transporter | Structural elements required for manganese efflux activity |
| TMEM94 (ERMA) | P-type ATPase for ER Mg2+ uptake | Endoplasmic reticulum magnesium homeostasis |
| SLC14A1 | Urea transporter | Urea permeation and inhibition mechanisms |
| SLC14A2 | Urea transporter | Urea permeation and inhibition mechanisms |
| SLC5A1 | Sodium-glucose cotransporter | Glucose transport physiology |
| SLC2A1 | Facilitative glucose transporter | Glucose transport physiology |
| LptC | LPS transport accessory protein | LPS extraction by LptB2FGC transporter |
| LptB | ABC transporter ATPase subunit | LPS transport across bacterial membranes |
| LptF | LPS transport subunit | LPS extraction by LptB2FGC transporter |
| LptG | LPS transport subunit | LPS extraction by LptB2FGC transporter |
| ABCB1 (P-glycoprotein) | Drug efflux transporter | Transporter-mediated drug interactions |
| ABCG2 (BCRP) | Drug efflux transporter | Transporter-mediated drug interactions |
| SLCO1B1 | Organic anion transporting polypeptide | Drug uptake and natural product interactions |
| SLC22A1 (OCT1) | Organic cation transporter | Drug uptake and natural product interactions |
| SLC16A2 (MCT8) | Thyroid hormone transporter | TRIAC transmembrane transport |
| SLC10A1 (NTCP) | Bile acid and drug transporter | Transporter-mediated drug interactions |
| ATP1A1 | Na+/K+-ATPase | Primary active ion transport |
How Is transmembrane transporter activity Regulated?
Transmembrane transporter activity is regulated at multiple levels, including transcriptional control, post-translational modifications, and interaction with ions and lipids. Ion and lipid orchestration of secondary active transport modulates conformational cycles and transport rates. In the endoplasmic reticulum, ERMA (TMEM94) P-type ATPase activity controls Mg2+ uptake and is essential for ER magnesium homeostasis. Transporters can also be regulated by accessory proteins, as shown for the LptB2FGC transporter where LptC participates in LPS extraction. Additionally, transporter-mediated natural product-drug interactions can alter transport activity and drug disposition.
transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC30A10 | Manganese efflux deficiency and neurotoxicity | Knockout and point-mutation cell models |
| TMEM94 (ERMA) | ER magnesium homeostasis and cellular stress | Knockout and knock-in models |
| SLC14A1/SLC14A2 | Urea transport and inhibition | Overexpression and point-mutation models |
| SLC16A2 (MCT8) | Thyroid hormone transport | Knockout and overexpression models |
| ABCB1/ABCG2 | Drug efflux and multidrug resistance | Knockout and overexpression models |
Manganese transport deficiency and neurodegeneration
Mutations in SLC30A10 impair manganese efflux activity, leading to manganese accumulation and associated neurological disease. Structural elements in the transmembrane and cytoplasmic domains of SLC30A10 are required for its manganese efflux activity, and loss of this function causes cellular manganese toxicity.
Endoplasmic reticulum magnesium homeostasis and disease
ERMA (TMEM94) is a P-type ATPase transporter for Mg2+ uptake in the endoplasmic reticulum, and its dysfunction impairs ER magnesium homeostasis. This can affect protein folding and cellular stress responses, linking transporter defects to broader disease mechanisms.
Urea transporter inhibition and therapeutic potential
Urea transporters mediate urea permeation, and structural insights reveal distinct inhibition modes that can be exploited for drug development. Targeting urea transporters may be beneficial in conditions where urea transport contributes to pathology.
Transporter-mediated drug interactions
Transporter-mediated natural product-drug interactions can alter drug absorption, distribution, and elimination, leading to changes in drug efficacy or toxicity. Understanding these interactions is important for predicting clinical outcomes and optimizing therapy.
From transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of transporter gene X alter substrate transport? | CRISPR knockout cell model [1,2,4] |
| Does a specific point mutation affect transport activity? | CRISPR point-mutation knock-in |
| Can a tagged transporter be used for localization studies? | Tagged knock-in |
| Does overexpression of transporter X increase drug efflux? | Overexpression cell model |
| Which transporters mediate uptake of a natural product? | CRISPR library screening |
| How does a disease-associated variant affect transport? | Knock-in of patient variant |
How to Study the transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate uptake | Transport rate and substrate specificity | Characterizing transporter kinetics [1,3] |
| Cryo-EM | Three-dimensional structure and conformational states | Mechanistic studies of transporters [3,8] |
| CRISPR knockout | Loss-of-function effects on transport | Identifying transporter genes [1,4] |
| CRISPR knock-in | Effect of specific mutations on transport | Modeling disease variants |
| Overexpression | Gain-of-function transport activity | Drug efflux studies |
| Proteomics | Transporter protein abundance and modifications | Expression profiling |
| Immunofluorescence | Subcellular localization | Organelle transport studies [2,5] |
| Library screening | High-throughput identification of transporters | Drug transport discovery |
Transport assays
Transport assays measure the movement of radiolabeled or fluorescent substrates across membranes to quantify transporter activity [1,3]. These assays can be performed in cell lines or reconstituted systems and are used to determine substrate specificity and kinetics.
Structural biology
Structural studies, including cryo-EM and X-ray crystallography, reveal conformational states and substrate-binding sites of transporters [3,8]. Such studies provide mechanistic insights into ion and lipid orchestration of secondary active transport.
CRISPR-based functional genomics
CRISPR knockout and knock-in screens enable systematic testing of transporter gene function and identification of genes involved in drug transport [1,4]. These approaches can link genotype to transport phenotype in a high-throughput manner.
Proteomics and imaging
Proteomics can quantify transporter expression and post-translational modifications, while imaging can localize transporters within cells [2,5]. These methods complement functional assays to provide a comprehensive view of transporter biology [2,5].
How CRISPR Can Be Used to Study GO:0022857 transmembrane transporter activity
Knockout
CRISPR knockout of transporter genes eliminates protein function and allows researchers to test whether a specific transporter is required for substrate transport [1,4]. For example, knockout of SLC30A10 can reveal its role in manganese efflux.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to test structure-function relationships, such as residues required for manganese efflux in SLC30A10. This approach helps distinguish loss-of-function from benign polymorphisms.
Knock-in
CRISPR knock-in can insert tags or disease-associated variants to study transporter localization and function in a physiological context [2,4]. Tagged knock-in of TMEM94/ERMA enables tracking of ER magnesium uptake.
Overexpression
CRISPR overexpression or cDNA overexpression increases transporter levels to study gain-of-function effects and drug transport. Overexpression of efflux transporters such as ABCB1 can increase drug resistance in cell models.
How EDITGENE Supports transmembrane transporter activity Research
Researchers studying transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in substrate transport, drug response, or disease. EDITGENE provides CRISPR-based cell model services to enable precise genetic manipulation and functional validation of transporters.
Contact EDITGENE today to design your custom CRISPR model for transmembrane transporter activity research.
Frequently Asked Questions About transmembrane transporter activity
What is GO:0022857 transmembrane transporter activity?
GO:0022857 is a molecular function term describing the activity that enables transfer of a substance, usually a specific substance or group of related substances, from one side of a membrane to the other.
What genes are involved in transmembrane transporter activity?
Genes encoding transporters include SLC30A10, TMEM94 (ERMA), SLC14A1, SLC14A2, SLC5A1, SLC2A1, LptC, and many others [2,3,4,5,6].
What diseases are linked to transmembrane transporter dysfunction?
Diseases include manganese efflux deficiency due to SLC30A10 mutations and ER magnesium homeostasis defects due to TMEM94/ERMA dysfunction [2,4].
How do transporters move substances across membranes?
Transporters undergo conformational changes that move substrates across the lipid bilayer, often coupled to ion or lipid gradients.
What is the difference between primary and secondary active transport?
Primary active transport uses ATP hydrolysis, as in P-type ATPases like ERMA (TMEM94), while secondary active transport uses pre-existing ion gradients [2,8].
How can I study transmembrane transporter activity in the lab?
Common methods include radiolabeled substrate uptake assays, structural biology, CRISPR knockout or knock-in, and proteomics [1,3,4].
What are transporter-mediated natural product-drug interactions?
These occur when natural products alter transporter activity and thereby change drug absorption, distribution, or elimination.
Which transporters mediate urea transport?
Urea transporters such as SLC14A1 and SLC14A2 mediate urea permeation and can be inhibited by specific small molecules.
What is the role of TMEM94 (ERMA) in the cell?
TMEM94 (ERMA) is a P-type ATPase transporter for Mg2+ uptake in the endoplasmic reticulum, important for ER magnesium homeostasis.
How does CRISPR help study transporter genes?
CRISPR enables knockout, point mutation, knock-in, and overexpression of transporter genes to test their function and role in disease [1,2,4].
Conclusion
Transmembrane transporter activity (GO:0022857) is a fundamental molecular function that controls the movement of ions, nutrients, drugs, and metabolites across biological membranes [1,8]. Its dysfunction is linked to human diseases such as manganese efflux deficiency and ER magnesium homeostasis defects, and it is a key determinant of drug disposition [1,2,4]. Advances in structural biology and CRISPR-based functional genomics continue to reveal the mechanisms and therapeutic potential of transporters [3,8]. Researchers can leverage EDITGENE services to create precise cell models and accelerate transporter research.
References
- 1. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
- 2. Vishnu N et al.. 2024. ERMA (TMEM94) is a P-type ATPase transporter for Mg(2+) uptake in the endoplasmic reticulum.. Mol Cell 84(7):1321-1337.e11 PMID: 38513662
- 3. Huang SM et al.. 2024. Structural insights into the mechanisms of urea permeation and distinct inhibition modes of urea transporters.. Nat Commun 15(1):10226 PMID: 39587082
- 4. Zogzas CE et al.. 2016. Structural Elements in the Transmembrane and Cytoplasmic Domains of the Metal Transporter SLC30A10 Are Required for Its Manganese Efflux Activity.. J Biol Chem 291(31):15940-57 PMID: 27307044
- 5. Wilson A et al.. 2022. The transmembrane α-helix of LptC participates in LPS extraction by the LptB(2) FGC transporter.. Mol Microbiol 118(1-2):61-76 PMID: 35678757
- 6. Oka Y. 1996. [Glucose transporter].. Nihon Rinsho 54(3):632-7 PMID: 8904216
- 7. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
- 8. Drew D et al.. 2024. Ion and lipid orchestration of secondary active transport.. Nature 626(8001):963-974 PMID: 38418916
